Graft-versus-leukemia (GvL
LLOGENEIC BONE MARROW transplantation (BMT)
offers not only the potential of applying marrow ablative doses of chemoradiotherapy, but also of inducing an immune-mediated antitumor effect referred to as graft-versus-leukemia (GvL)."~ Evidence for a substantial GvL effect is given by retrospective analysis of clinical BMT in hematologic malignancies and from experimental tumor model^.'^^^^-^ Isolation of donor cytotoxic T lymphocytes from patients with graft-versus-host disease (GvHD) capable of killing host leukemic cells has provided additional support and pathophysiologic insights into the mechanisms of GvL effects, permitting a search for target molecules of GvHD and GvL.~." Until recently, little was known about the molecular nature or the biological properties of these antigens called minor histocompatibility antigens (MiHAs), mainly due to the lack of recognition by antibodies. Recent findings indicate that MiHAs are peptides derived from cellular proteins, which are presented to T cells by major histocompatibility complex (MHC) molecules in the same way as viral antigens and expressed on normal hematopoietic (eg, progenitors, B and T lymphocytes, monocytes), epithelial (eg, keratinocytes, fibroblasts, gut, liver), and malignant hematopoietic cells.'"'' One of these peptides was recently isolated and biochemically characterized." It is still unknown, however, whether such MiHAs are also expressed on malignant epithelial cells and, if so, whether this finding has any clinical implications with respect to a graft-versus-tumor (GvT) effect.
A clinically relevant antitumor effect for solid tumors in vivo has not been demonstrated so far. The low frequency of allogeneic BMT for solid tumors (30 patients in Europe during the last 5 years" and none with breast cancer) might well account for the lack of information about this important issue.
In this article we report on a patient with breast cancer transplanted with bone marrow from her HLA-identical sister. Disappearance of liver and bone metastases observed simultaneously with clinical GvHD on day +27 and the presence of MiHA-specific cytotoxic T lymphocytes recognizing breast carcinoma cell lines suggest that a GvT effect might also be operative in patients with breast cancer after allogeneic BMT. 
MATERIALS AND METHODS

Isolation of peripheral blood mononuclear cells (PBMC).
Heparinized peripheral blood was obtained from the donor and from the patient before transplantation and on day +27 during GvHD. PBMC were separated on Ficoll-Isopaque (Lymphoprep; Nyegaard, Oslo, Norway), washed three times, and stored in liquid nitrogen until use.
Establishment of cytotoxic T-cell line (CTLJ. CTL was established as previously described." In short, 2 X 106/mL posttransplant recipient PBMC harvested during GvHD were stimulated with 2 X 106/mL irradiated (30 Gy) pretransplant recipient PBMC and cultured in a 24-well plate (2 mWwell; Costar, Cambridge, MA) using tissue culture medium consisting of RPM1 1640 (Biochrom, Berlin, Germany) containing 2 mmoVL L-glutamine (Biochrom), 100 U/nL penicillin (Biochemie, Vienna, Austria). and 20 U/mL streptomycin (Biochemie) supplemented with 10% human male AB pool serum at 37°C in a humidified 5% C0,/95% air atmosphere. On day 6, cells were adjusted at a concentration of 2 X 10s/mL and restimulated with 4 X 105/mL irradiated (50 Gy) Epstein Barr Virus (EBV)-transformed, pretransplant recipient PBMC in tissue culture medium supplemented with 2% high-purity Lymphokult-T (Biotest, Dreieich, Germany), final concentration as interleukin-2 source. Every third day, 50% of the medium was replaced with fresh medium containing 20% Lymphokult-T (Biotest) at final concentration. CTL obtained Establishment of EBV-transformed lymphoblastoid cell lines (LCL) and phytohemagglutinin (PHA) blasts. Pretransplant recipient and donor PBMC were resuspended in tissue culture medium supplemented with 10% FCS at a concentration of 2 X IO'/mL and mixed with the same amount of a mycoplasma-free EBV producer line B95-8 supernatant and 200 ng/mL cyclosporine A (CsA, Sandimmun; Sandoz, Vienna, Austria). On day 6 and every third day thereafter, 50% of the culture medium was replaced with fresh medium. CsA was added to the culture until the third week. PBMC ( 1 X 10'/mL) from the host and the donor were incubated with 1% PHA (Difco, Detroit, MI) in a humidified 5 % C02/95% air atmosphere at 37°C for 72 hours. For further growth, cells were cultured in tissue culture medium supplemented with 20 U/mL recombinant 1L-2 (Hoffmann-La Roche, Basel, Switzerland).
Cell-mediated lympholysis (CML) ussu.~. CML assays were performed as previously described." In short, 2 X IO" target cells (both donor and recipient PHA blasts, LCL and breast cancer cell lines pretreated for 72 hours with the following cytokines: 0 , 10, 100, 1 .000 U/mL interferon [ IFNI-y, 1,000 U/mL IFN-a and 1,000 U/mL tumor necrosis factor [TNFI-a were labeled with 250 pCi NazCrS'04 (specitic activity 300 to 500 Ci/g chromate; NEN, Dreieich, Germany) for 2 hours at 37"C, washed four times, and resuspended at a concentration of 5 X 10' cells/mL. Of the target cells, 100 p,L was incubated in U-shaped microtiter plates (Falcon; Becton Dickinson, Lincoln Park. NJ) with 100 pL of various amounts of effector cells with E:T ratios ranging from 50: 1 to 6: I . After 4 hours incubation at 37°C in a humidified 5% C0,/95% air atmosphere, 100 pL of the culture supernatant was counted with a gamma-scintillation counter (LKB, Stockholm, Sweden). Experimental release represents cpm released from the target cells incubated with the effector cells; spontaneous release is that from target cells cultivated without effector cells; maximum release is cpm released from target cells after 4 hours incubation with 2% Triton X-100 (Sigma, Deisenhofen, Germany).
Blocking experiments. The following monoclonal antibodies (MoAbs) were used to block the CML assay: anti-HLA-AB (MAS 1532, clone W6/32; Seralab, Crawley Down, Sussex, UK) and anti-HLA-DR (clone L 243; Becton Dickinson) MoAb against common determinants on class I and class 11 MHC molecules, respectively: BB 7.2 directed against HLA-A2.'6 Target cells (5,000/well) resuspended in 50 pL tissue culture medium were incubated with 50 pL MoAb (10 pg/mL) for 30 minutes at room temperature. Effector cells were then added to the target cells as described above. regimen.3x Successful engraftment, defined as the first of two consecutive days with more than 1.000 leukocytes/pL and self-sustaining hematopoiesis, was achieved on day + 13 and the patient was discharged on day + 18. Complete hematopoietic chimerism was documented 3 weeks after BMT by isoenzyme analysis in peripheral blood mononuclear cells.
The further posttransplant course was uneventful until day +27, when a biopsy-proven acute GvHD grade + +/+ + + of the skin developed. Treatment with methylprednisolone was started for progressive GvHD at a dosage of I mgkg body weight. On the same day, CT scan ( Fig IC) documented complete resolution of the liver metastases. Methylprednisolone was discontinued after GvHD had resolved. On day +58 the patient was readmitted to the hospital because of fever of unknown origin, which 4 days later was documented as being due to bacterial meningitis caused by Listeria monocytogenes.
The infection resolved after appropriate antibiotic treatment.
CsA was tapered and discontinued on day 80. Two weeks later, metastases in the liver (Fig ID) were documented on CT scan and the patient was discharged. The patient died on day 1 IO after BMT due to progressive liver metastases. As confirmed by autopsy, no further metastases were detected and no bone metastases were found in the spine.
At the time of GvHD (day +27), cytotoxic T lymphocytes recognizing host pretransplant cells (T cells and LCL) but not HLA-identical donor cells and therefore defined as MiHAspecific were grown from the peripheral blood of the patient (Fig 2) . Recognition was MHC class I antigen-restricted. as shown by blocking experiments with MoAb against common determinants on MHC class I and I1 antigens.
Since a breast cancer cell line of the patient could not be established, CTL were tested against a panel of eight breast (Fig 3) . HLA-A2 was the predominant restricting element since lysis was blocked by a MoAb against HLA-A2 (Fig 4) . Despite expressing HLA-A2, MDA MB, and SKBR-3 cell lines were not recognized by the CTL.
In previous publications we indicated the key role of cytokines in regulating susceptibility of GvHD (keratinocytes) and hematopoietic cell targets".37.39 and showed that IFN-y was able to increase lysis of keratinocytes by its capacity to increase MHC class I antigen expre~sion."~~' In order to investigate the mechanisms involved in carcinoma cell lysis the four recognized carcinoma lines were used as targets in the CML assay after pretreatment with IFN-y, IFN-a and Fig 1 kont'dl. TNF-a. Interestingly, only pretreatment with TNF-a (1 , O00 U/mL), but not with IFN-y or IFN-a, increased lysis ( Fig  5) . In order to elucidate the mechanisms of these findings in more detail, flow cytometric analyses of the cytokinepretreated and untreated breast cancer target cell lines were performed with MoAb against MHC antigens and adhesion molecules. As shown in Table 1 , all three cytokines except TNF-a were able to increase MHC class I antigen expression. IFN-y was the only cytokine that induced de novo MHC class I1 antigen expression. TNF-a was the only cytokine increasing LFA-3 and CD2 expression. IFN-y and TNFa induced ICAM-I expression, but none of the cytokines induced LFA-I expression. 40 treatment of patients with metastatic solid tumors or as consolidation in high-risk patients.4042 While treatment-related mortality is low, relapse of the disease remains the major o b~t a c l e .~.~~.~~ Uncontrolled phase I and I1 studies have suggested that 15% to 20% of women with metastatic breast cancer will achieve durable complete remissions. The majority of patients with metastatic breast cancer, however, will relapse and the published data suggest that the median time to relapse or death is not greatly delayed by the addition of high-dose consolidation therapy.4649 Even total eradication of metastases by surgical means (resection or organ replacement) and treatment of the minimal residual disease by autologous BMT did not cure such patient^.^^*^' In the search for other approaches and considering an antitumor effect of GvHD and of donor lymphocyte infusions after relapse following allogeneic BMT for hematologic diseases, adoptive immunotherapy resulting from allogeneic BMT may represent a potential tool for more effective therapy for metastatic breast cancer patients. In one patient refractory to chemotherapy and with no other curative option, we investigated 
DISCUSSION
During recent years, high-dose chemotherapy and autologous stem cell support have increasingly been used for the
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the possibility of a GvT effect by analyzing her clinical course and the specificity and antitumor activity of circulating CTL during GvHD. In this patient a complete disappearance of liver metastases concomitant with severe GvHD of the skin was observed 27 days after BMT. Disappearance of liver and bone metastases could theoretically be due to high-dose chemotherapy alone. The following evidence, however, argues in favor of a possible GvT effect: first, progression of liver and appearance of bone metastases during chemotherapy before BMT, second, lack of such dramatic responses in patients with refractory metastatic breast cancer after autologous BMT; and, third, the presence of circulating MiHA-specific CTL, recognizing breast carcinoma target cells at the time of metastases regression. MiHAs have been shown to play a major role in GvHD and GvL effect after allogeneic BMT and their tissue distribution has been shown to be heterogeneous with either ubiquitous or a more cell-type confined e x p r e s s i~n . " .~~.~~ While ubiquitous MiHAs are expressed on cells of different origins (eg, hematopoietic and epithelial), the latter are expressed be primarily involved in controlling breast cancer cell lysis. LFA-3 density distribution might be one of these surface molecules, since its increased expression was exclusively seen after TNF-(Y pretreatment and paralleled enhanced susceptibility of these cells to CTL.
Since tumor-specific antigens (eg, MAGE-l) recognized by cytotoxic lymphocytes have also been found on breast tumors, we cannot exclude the possibility that a GvHDindependent GvT effect also operates in patients with breast cancer.52 In vitro experiments investigating this aspect are in progress.
Despite evidence for a graft-versus-breast cancer effect. the patient relapsed after BMT. Reasons for this failure may include local factors such as site of metastases and encapsulation. where CTL might not penetrate. and also the large tumor burden present before BMT. Treatment of acute GvHD with steroids might have hampered the GvT effect as well." Similar observations have also been made in pa- 
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For personal use only. on October 3, 2017. by guest www.bloodjournal.org From GRAFT-VERSUS-TUMOR EFFECT FOR BREAST CANCER 1507 tients with advanced hematologic diseases, where, despite GvHD, relapse rates of more than 50% are seen in patients with large tumor burden before tran~plant.~~ These data show that a slightly modified STAMP V conditioning regimen, recently used only in autologous BMT, permits allogeneic engraftment. 55 They further suggest that a GvT effect might exist after allogeneic BMT for breast cancer. As with leukemia, larger numbers of patients receiving allogeneic BMT for breast cancer would be required to determine whether a GvT effect produces a clinically relevant response.
